Literature DB >> 27502123

Frontotemporal dementia: from molecular mechanisms to therapy.

Christian Haass1,2,3, Manuela Neumann4,5.   

Abstract

Frontotemporal dementia (FTD) is a heterogeneous clinical syndrome characterized by frontotemporal lobar degeneration (FTLD). Neuropathologically, FTLD is characterized by abnormal protein deposits and almost all cases can now be classified into three major molecular subgroups based on specific accumulating proteins with the most common being FTLD-tau and FTLD-TDP (accounting for ~40% and 50%, respectively) and FTLD-FET (accounting for ~5-10%). In this special issue, the molecular and genetic basics as well as clinical approaches and therapeutics are reviewed in a series of articles. This article is part of the Frontotemporal Dementia special issue.
© 2016 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27502123     DOI: 10.1111/jnc.13619

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

1.  Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia.

Authors:  Angela She; Iren Kurtser; Surya A Reis; Krista Hennig; Jenny Lai; Audrey Lang; Wen-Ning Zhao; Ralph Mazitschek; Bradford C Dickerson; Joachim Herz; Stephen J Haggarty
Journal:  Cell Chem Biol       Date:  2017-07-14       Impact factor: 8.116

2.  Young-onset frontotemporal dementia with FUS pathology.

Authors:  Matthew Gowell; Ian Baker; Olaf Ansorge; Masud Husain
Journal:  Pract Neurol       Date:  2020-12-11

Review 3.  Caenorhabditis elegans Models to Investigate the Mechanisms Underlying Tau Toxicity in Tauopathies.

Authors:  Carmina Natale; Maria Monica Barzago; Luisa Diomede
Journal:  Brain Sci       Date:  2020-11-11

Review 4.  From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline.

Authors:  Rajka Maria Liscic; Antonella Alberici; Nigel John Cairns; Maurizio Romano; Emanuele Buratti
Journal:  Mol Neurodegener       Date:  2020-06-01       Impact factor: 14.195

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.